Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Dianne Whitfield Sells 4,174 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne Whitfield sold 4,174 shares of Tarsus Pharmaceuticals stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $279,658.00. Following the completion of the sale, the insider directly owned 35,028 shares in the company, valued at approximately $2,346,876. This represents a 10.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS opened at $66.75 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85. The stock has a 50 day moving average price of $69.36 and a 200 day moving average price of $70.18. The stock has a market capitalization of $2.84 billion, a PE ratio of -41.20 and a beta of 0.55. Tarsus Pharmaceuticals, Inc. has a 52 week low of $38.51 and a 52 week high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Key Stories Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published tighter quarterly and FY‑2026 EPS forecasts (smaller expected losses vs. consensus), which supports a more constructive growth/recovery thesis for the stock. Read More.
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s upgrade improves outlook but does not represent unanimous conviction across all analysts. Read More.
• Neutral Sentiment: Company fundamentals: most recent quarter showed a slight EPS miss (reported ($0.20) vs. ($0.19) estimate) but revenue beat, leaving fundamentals mixed and dependent on future trial/launch catalysts. Read More.
• Neutral Sentiment: High institutional ownership (~90%) is a double‑edged factor — it stabilizes float but means large holders can move the stock if they adjust positions. Read More.
• Negative Sentiment: Significant insider selling disclosed in multiple Form 4s between Mar 16–19: CEO Bobak Azamian sold ~10.9k–12.0k shares across several days (prices ~ $67–$69), director William J. Link sold 12,500 shares (~$68.79), and several other senior officers also reduced stakes — these large, clustered sales can create immediate downward pressure and raise questions about near‑term liquidity needs or portfolio rebalancing. Read More.

Analyst Ratings Changes

TARS has been the subject of a number of analyst reports. Zacks Research downgraded shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Lifesci Capital raised Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Finally, Guggenheim increased their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $91.83.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. TimesSquare Capital Management LLC bought a new position in shares of Tarsus Pharmaceuticals during the third quarter worth approximately $15,898,000. Jennison Associates LLC boosted its stake in Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock valued at $154,790,000 after purchasing an additional 136,582 shares during the period. TFG Asset Management GP Ltd grew its holdings in Tarsus Pharmaceuticals by 40.1% in the 2nd quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock valued at $10,128,000 after buying an additional 71,530 shares in the last quarter. Capricorn Fund Managers Ltd acquired a new position in Tarsus Pharmaceuticals in the 3rd quarter valued at $14,264,000. Finally, Jump Financial LLC increased its position in Tarsus Pharmaceuticals by 385.9% during the 2nd quarter. Jump Financial LLC now owns 237,117 shares of the company’s stock worth $9,606,000 after buying an additional 188,317 shares during the period. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.